HP 802247

Drug Profile

HP 802247

Alternative Names: Allogeneic human skin replacement - Smith & Nephew Biotherapeutics; Allox™; DFB Healthpoint allogeneic human skin replacement; HP-802247; Human skin replacement - Smith & Nephew Biotherapeutics

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator Healthpoint
  • Developer Smith & Nephew Biotherapeutics
  • Class Cell therapies; Skin disorder therapies
  • Mechanism of Action Fibrinogen replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Leg ulcer; Wounds

Most Recent Events

  • 23 Feb 2015 Smith & Nephew terminate a phase III trial in Leg ulcer in Czech Republic, Poland, Hungary, Belgium and Germany due to the outcome of previous study (NCT01853384)
  • 16 Jan 2015 Smith & Nephew terminates phase II trial in Leg ulcer in USA (NCT02154087)
  • 01 Dec 2014 Healthpoint completes a phase III trial for Leg ulcer in USA and Canada (NCT01656889)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top